Polyrizon

Company Overview

Snapshot

Founded in March 2020 by Tomer Izraeli, Polyrizon operates with 1–10 employees. The company has raised a total of $27.03 million across nine funding rounds and went public on NASDAQ in October 2024.

Business overview

Polyrizon is a biotechnology company specializing in the development and commercialization of innovative intranasal products. Its core technology includes the Capture & Contain (C&C) platform, a natural 3D polymeric network designed to create a physical barrier against airborne contaminants like allergens, viruses, and molds. Additionally, its Trap & Target (T&T) platform provides targeted delivery of medicines to mucosal tissue for improved therapeutic effects. The company operates within the Health Tech & Life Sciences sector, focusing on drug delivery solutions for various applications.

Strategic signal

Polyrizon is making significant strides in its clinical development, as evidenced by securing three U.S. sites for its NASARIX™ Allergy Blocker clinical trial in June 2026 and receiving Central IRB approval for the trial. This progress indicates a strong push towards regulatory approval and commercialization of its key product, signaling potential for near-term growth and market entry in the allergy treatment space.

Company Intelligence Q&A

What was a significant recent regulatory milestone for Polyrizon?

In June 2026, Polyrizon received Central IRB Approval for its Allergy Blocker Clinical Trial, marking a crucial step forward in its clinical development pathway.

What recent progress has Polyrizon made in its NASARIX™ Allergy Blocker clinical trials?

In June 2026, Polyrizon secured three U.S. sites for its NASARIX™ Allergy Blocker clinical trial, demonstrating strong clinical progress towards its planned studies.

When did Polyrizon expand its patent portfolio for its intranasal drug delivery platform?

In May 2026, Polyrizon announced a U.S. patent expansion for its intranasal drug delivery platform, strengthening its intellectual property in this area.

What strategic move did Polyrizon announce in March 2026 regarding its portfolio?

In March 2026, Polyrizon announced its intention to acquire up to a 20% stake in Colugo, a developer of advanced eVTOL Drones for defense and urban air mobility applications, indicating a potential diversification of its interests.

What was a key development in Polyrizon's manufacturing for its clinical studies?

In March 2026, Polyrizon announced the GMP manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for its planned U.S. clinical study, ensuring readiness for human trials.